China claims to find strong antibodies against COVID-19 varian Delta. This was announced by Chinese vaccine manufacturer Sinopharm on Wednesday.
According to them, these antibodies are effective in preventing the Delta variant of COVID-19 in the short term and can be used as a treatment for Corona virus infection.
Research led by Yang Xiaoming, chairman of Sinopharm China National Biotec Group, a subsidiary of Sinopharm, reveals that monoclonal antibodies are effective in blocking binding corona virus new in Angiotensin 2 converting enzyme.
Quoted from the Global Times, this enzyme is attached to the cell membrane. Located in the intestines, kidneys, testes, gallbladder, to the heart. These antibodies can prevent the virus from infecting cells.
This monoclonal antibody is expected to have high efficacy as a therapeutic drug, with low toxicity. The antibody, called 2B11, is also claimed to reduce lung inflammation caused by viral infections.
As is known, the Delta variant is increasingly dominating in more than 100 countries including China to Indonesia. The new study explains that 2B11 has neutralizing activity in the Delta variant to a large application value that can be used for and early treatment.
The company hopes that this therapy can be used in prevention and control COVID-19 in China as soon as possible. This research is also expected to be a useful weapon against new mutations of the Corona virus.
Watch Videos”Is it true that the Delta Variant Corona Virus can be transmitted by passing?“
[Gambas:Video 20detik]
(naf/up)
– .
